Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: harmonaronson who wrote (1741)	9/25/2000 12:03:30 PM
From: keokalani'nui	Respond to of 52153

Only you can evaluate your own suitablility. Personally, For a 5-year hold, I would select a few more therapeutics. From your list you may be more comfortable with the 1st tier, so you may not be interested in ALXN and NBIX but those are two you may enjoy investigating. You didn't ask, but holding only 5 sounds like a lot of risk to me. As few as 8 is still keeping the throttle wide open and just MIGHT allow you to survive 5 years, since with eight you should expect the same number of near-death experiences, or more. --Wilder

To: harmonaronson who wrote (1741)	9/28/2000 1:03:25 PM
From: Biomaven	Respond to of 52153

harmon, I agree with wilder that 5 stocks may not be enough in biotech. I can't really argue with your list, although CRA remains pretty unclear to me and AFFX seems to be beset by threats of new competition (although it's very hard to judge how real the threats are). I would definitely also consider SEPR and maybe some lower tiers as well - wilder's ALXN and NBIX (both of which are significant holdings for me) are also interesting places to look. VRTX is another good candidate in the same style as your list. None of these stocks are particularly cheap any more. For cheap, you definitely have to drop a tier or two. Peter

To: harmonaronson who wrote (1741)	9/28/2000 1:15:18 PM
From: Robert Rose	Respond to of 52153

harmon, take a look at bbh, a basket of 20 biotechs allocated by market cap. If you don't have a clue about biotech but believe in the sector's potential, it's a good bet. I then add an occasional more speculative issue to augment this core holding: cege (not really very speculative, imo) nexl, and most recently dndn. fwiw.